Axa S.A. Acquires 4,707 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Axa S.A. increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 12.8% during the fourth quarter, HoldingsChannel reports. The firm owned 41,471 shares of the company’s stock after acquiring an additional 4,707 shares during the period. Axa S.A.’s holdings in Harmony Biosciences were worth $1,427,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Barclays PLC raised its holdings in Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company’s stock valued at $3,074,000 after acquiring an additional 40,416 shares during the period. Franklin Resources Inc. grew its stake in Harmony Biosciences by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 29,773 shares of the company’s stock worth $1,191,000 after buying an additional 1,720 shares in the last quarter. JPMorgan Chase & Co. raised its position in Harmony Biosciences by 68.4% during the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after purchasing an additional 93,622 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after buying an additional 436 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its holdings in shares of Harmony Biosciences by 27.0% in the 4th quarter. CWA Asset Management Group LLC now owns 18,279 shares of the company’s stock worth $629,000 after acquiring an additional 3,883 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Performance

HRMY stock opened at $34.09 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 1 year low of $26.47 and a 1 year high of $41.61. The company has a market cap of $1.96 billion, a P/E ratio of 16.16, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The stock’s fifty day moving average price is $31.35 and its 200-day moving average price is $34.01.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. The business had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. On average, equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group reduced their price target on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. Needham & Company LLC reissued a “buy” rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday. Mizuho upped their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $52.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.